Ascendis Pharma gains amid takeover speculation
Source: SeekingAlpha
2025-12-12 15:24:38 ET
More on Ascendis Pharma
- Ascendis: Q3 Results Validate The TransCon Platform
- Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
- Ascendis dwarfism drug candidate review extended by FDA
- Ascendis Pharma GAAP EPS of - €1.00, revenue of €213.63M
- Seeking Alpha’s Quant Rating on Ascendis Pharma
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma gains amid takeover speculation
Ascendis Pharma A/S
NASDAQ: ASND
ASND Trading
-1.15% G/L:
$220.79 Last:
324,009 Volume:
$220.68 Open:
ASND Latest News
March 17, 2026 08:30:00 am
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
ASND Stock Data
$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup
